Exchange: NYSEMkt·Updated 02:33 PM EST
ATNM logo

ATNM Actinium Pharmaceuticals Inc

$1.33
$0.16
(10.74%)
Today
Reported EarningsJul 28
Mkt Cap$46.85M
Vol427,756.00

About ATNM

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, discovery, and clinical development of targeted radiotherapies. It also develops and markets medicines for relapsed and refractory cancer patients. The company was founded in 2000 and is headquartered in New York, NY.
36

Bearish Sentiment

How do you feel about ATNM?

DENDOG57
$ATNM i believe this is about to hit and hit big... lots of great things in the works that will help millions
24
yellowjacker
$ATNM The real catalyst in the data room right now is Actimab-A in Phase 2-3 trials being done by the National Cancer Institute on AML. Under CRADA, the frontline Phase 2-3 triple Trial data for Actimab-A+ Venetoclax+ASTA-727 data is being clean up by Dr. David, and view in the data room by Big Pharma. Don't get me wrong, ATNM-400 is for real, but Actimab-A is the safety net. In past a trial using chemotherapy and Actimab-A on AML patient, over 55 with no other treatment options having a complete remission in the 70% range. If the numbers are good for the triple-Phase 3 trial, being administered by the NCI, an FDA application is sooner rather than later. The second selling point or catalyst is the supply chain in patents and logistics of AC-225. If you are the owner of Venetoclax or ASTA-272 and you are seeing good data, do you act now, or wait and be at the mercy of the players seeking to control ACC-225? Iomb-B down the road will be the cherry on top, who also had outstanding numbers
18
englishkaren
$ATNM $ATNM $MRK — One to watch Monday, October 26: Merck’s Oncology Investor Event at ESMO, 2:30 PM ET. Merck will outline its oncology strategy and pipeline priorities. Of particular interest to ATNM investors will be any discussion of radiopharmaceuticals, Actinium-225, HER3-targeted therapies, licensing or acquisitions. Actinium has just presented encouraging first-in-human ATNM-400 results, demonstrating HER3-targeted tumour uptake, no dose-limiting toxicities in its initial three-patient cohort, and progression to the second dose level. Merck already has an interest in HER3-directed oncology through its collaboration with Daiichi Sankyo. No confirmed connection between Merck and Actinium, but the timing makes Monday’s presentation worth watching closely.
18
Investfaithfully
$ATNM please get in now because this is gonna take off there’s so many pharmaceutical companies that will benefit astronomically by purchasing us !!
17
pmckillop5
$ATNM I have been a shareholder for over five years, and I have lost a lot of money. I'm the first to agree that the company has made a lot of mistakes in communicating with shareholders. However, I do believe in the science and the good it will do for cancer patients. Recent hires at the company reflect a new level of talent, and I'm hopeful they will be allowed to perform and execute so that shareholder value will increase based on the good it will do for patients. Good luck to all longs!
17
yellowjacker
$ATNM The Chemo study mentioned in the last post was a Phase 2-3 study involving CLANG-M + Actimab-A. This study produced an 83% overall no-response rate and a 75% MRD negativity rate, indicating complete eradication of all cancer cells.
16
yellowjacker
$ATNM What I saw in this week's volume and price. Selling in the morning hours and accumulation at the end of the day. Today's action going into Friday's close puts the Share price close to the high of the week, around $1.65. Waiting for the 3rd quarter earnings report.
14
fede5910
$ATNM The market is expecting a stock dilution, if this happens it’s another fraud against ATNM’s shareholder. I really hope you don’t disappoint the shareholder again, ATNM has to keep moving forward without diluting.
8
Reformedwallstreeter
$ATNM a whopping $42 million of market cap here…if there is any inkling that this is REAL the first stop should be $200 million or about $6 a share…then up from there as it is proved….
15
alcacer123
$ATNM Welcome to the small-cap pharma sector, where things that might seem strange to you happen quite often. That’s what it’s all about, and that’s why I invest in them. If you find it far-fetched for a stock to go up 100-fold, then stick to buying IBM or Intel. I believe that, as of today, ATNM holds significant value for a "Big Pharma" company. It doesn’t need to make much more progress in terms of data—but if it does, it will be worth a great deal more.
14
fede5910
$ATNM I understand that all the public relations that ATNM is providing are a clear sign to potential buyers of the company. ATNM wants to sell its science in the short term, and if this is true and accurate, the cash it has today is more than enough to meet all its commitments. For this reason, it shouldn’t harm its shareholders, who have long hoped that ATNM could demonstrate its ability and excellence in advancing its science.
7
johnny4cures
$ATNM What today's announcement really adds is not immediate revenue. It adds evidence that management is actively executing a pan-cancer HER3 strategy in humans rather than discussing one conceptually. The RADIANZ study is enrolling multiple tumor types specifically to evaluate biodistribution, uptake, PK, and dosimetry beyond prostate cancer. Combined with the NCI-supported GBM/basket programs testing the MDSC/checkpoint hypothesis, you now have: Plain Text Platform Validation Effort #1 HER3 Platform Validation Effort #2 MDSC / Immune running simultaneously. That's why, in your framework, the strategic value grows faster than the asset value. The market is no longer being asked to believe in one product. It's being asked to evaluate whether multiple platforms can work together. The biggest remaining uncertainty is still clinical validation, but today's PR arguably strengthens the platform thesis more than it changes any single-product valuation.
13
johnny4cures
$ATNM M&A Read If you're a buyer, the cost-of-waiting argument gets stronger as those milestones approach because a successful sequence could look like: Plain Text Facility online + DL3 + More uptake data + First efficacy signals + Basket trial Each step potentially removes risk. That's why the timeline matters more than the absolute cash balance. The strongest strategic interpretation of the milestone schedule is: Management appears to be positioning the company to create additional value over the next several quarters rather than simply maintaining the status quo. Whether that culminates in independent development, partnerships, financing, or a future acquisition is not something the filings tell us. But the milestone cadence certainly supports the argument that the value of the company could be very different 6-12 months from now if execution continues successfully.
8
BruceSr
$ATNM From looking at the very low volume so far today, it looks like many of us know what we have and are not going to sell our shares for pennies! The opportunities ahead are just too great to take chances.
13
englishkaren
$ATNM The employment agreement for newly appointed CFO Matt David contains a specific financing provision. It provides for 75,000 performance-based RSUs linked to equity financing completed by February 5, 2027. Financing completed CFO RSUs vesting Less than $20 million None under this provision $20 million to less than $30 million 50,000 $30 million or more 75,000 The financing must involve selling Actinium common shares to third-party investors. It establishes that the board has created an incentive for the CFO to secure a substantial equity financing within a relatively short period. Nevertheless, when considering the $28.68 million cash balance and increasing operating expenditure, this provision deserves more attention than general statements about the company's cash runway. The deadline is approximately 11 weeks after the November filing.
8
Slainte13579
$ATNM truly an exciting time not only for shareholders but for the patients who need our help!
13
johnny4cures
$ATNM ⭐ Every pharma company presenting HER3 upregulation, HER3 escape, or HER3 resistance data is unintentionally mapping out the exact tumors Actinium’s HER3‑alpha therapy will target — and dominate — in the future. Let me break this down cleanly, using your preferred analytical style. ⭐ 1. Why HER3 upregulation data from other companies benefits ATNM HER3 upregulation = HER3 turns on when tumors become resistant. This is being shown by: Daiichi (HER3‑DXd) Merck (HER3 escape in EGFR/KRAS/PD‑1 failures) AstraZeneca (HER3 signaling in EGFR‑mutant NSCLC) Roche/Genentech (HER3 activation in HER2‑resistant breast cancer) Novartis (HER3 escape in HER2/ADC resistance pathways) Pfizer (HER3 expression in metastatic breast cancer) Every one of these companies is showing: ✔ HER3 is a universal escape node ✔ HER3 is upregulated in resistance ✔ HER3 is a pan‑tumor target ✔ HER3 is a CNS‑active target ✔ HER3 is a metastatic driver ✔ HER3 is a salvage pathway
1
10
SexyStockSlayer
$ATNM undiscovered with great PR this morning Actinium Pharmaceuticals Unveils ATNM-400 Data at EANM 2026 with a First-In-Human HER3-Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer By PR Newswire | October 20, 2026, 8:00 AM
13
BruceSr
$ATNM Well I think that we have shown our … “proof-in-the-pudding”…and we’re off to the next phase. At this stage of our success and unique patented protected progress attacking cancer ANYTHING could happen with BP (partnership or buyout) at ant time! BP SURPRISES may be just around the corner!!! IMHO…It’s time to BUY-n-HOLD your shares!!!!!
13
Chippy_the_Cat
$ATNM although I am not a fan of how Seth has (not) interacted with shareholders, it is clear he is running a tight ship behind the scenes. You don't put out this many abstracts without A LOT of high quality research happening behind the curtain. Excited for the future.
12

Advertisement|Remove ads.